Use of electronic alerts in clinical practice has had mixed effects on providers' prescribing practices. Little research has explored the use of electronic alerts for improving screening practices. New York City has one of the highest rates of HIV in the United States. Recent New York State legislation requires healthcare providers to offer an HIV test to patients aged 13-64 years during a clinical encounter. Adhering to this requirement is particularly challenging in emergency department (ED) settings, which are frequently overcrowded and under-resourced. The purpose of this study was to evaluate the effect of an electronic "hard-stop" alert on HIV testing rates in the ED. Approximately four months of data were reviewed before and after the implementation of the alert. We found that use of the electronic alert significantly increased documentation of offering an HIV test (O.R. = 267.27, p<0.001) and resulted in a significant increase in HIV testing. Findings from this study add to the current knowledge about the use of electronic alertsfor improving disease screening.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104197 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Community Perspectives on Optimizing Community Health Volunteer Roles for HIV Prevention Services in Kenya and Uganda.
AIDS Patient Care STDS
January 2025
Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA.
Community health workers (CHWs) play a significant role in supporting health services delivery in communities with few trained health care providers. There has been limited research on ways to optimize the role of CHWs in HIV prevention service delivery. This study explored CHWs' experiences with offering HIV prevention services [HIV testing and HIV pre- and post-exposure prophylaxis (PrEP and PEP)] during three pilot studies in rural communities in Kenya and Uganda, which aimed to increase biomedical HIV prevention coverage via a structured patient-centered HIV prevention delivery model.
View Article and Find Full Text PDFCurrent methods for detecting and assessing HIV-1 antibody resistance.
Front Immunol
January 2025
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Antiretroviral therapy is the standard treatment for HIV, but it requires daily use and can cause side effects. Despite being available for decades, there are still 1.5 million new infections and 700,000 deaths each year, highlighting the need for better therapies.
View Article and Find Full Text PDFDelays in Blood Work and Disease Burden: A Cross-Sectional Analysis of Unmet Blood Work Need and Seven Key Health Conditions Across 21 Countries.
Int J Public Health
January 2025
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States.
Objectives: This study analyzes survey data across 21 countries to explore correlations between delays in blood testing and the prevalence of seven health conditions: thalassaemias, sickle cell disorders, malaria, HIV, high fasting plasma glucose, impaired kidney function, and high LDL cholesterol.
Methods: We analyzed Pandemic Recovery Survey data via multivariable logistic regression to compare blood test delays between individuals with and without medical conditions, while adjusting for sociodemographic factors. We also examined the disease burden using disability-adjusted life years (DALYs) and summary exposure values (SEV) rates.
Atherogenic Index of Plasma and High-Sensitivity C-Reactive Protein Levels Among People Living With HIV on Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy and Their Correlations to CD4 Cell Counts.
AIDS Res Treat
January 2025
Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Atherogenic index of plasma (AIP) and high-sensitivity C-reactive protein (hsCRP) levels which are strong predictors of the risk of cardiovascular disease (CVD) seen elevated in the serum of people living with HIV (PLWH) on HAART and in those with low cluster of differentiation-4 (CD4) cell counts. Thus, this study aimed to evaluate AIP and hsCRP levels among PLWH on dolutegravir (DTG) and ritonavir-boosted atazanavir-based (ATV/r) antiretroviral therapy (ART) and their correlations to CD4 cell counts. The study design was an institutional-based comparative cross-sectional study conducted from November 4, 2021, to January 4, 2022.
View Article and Find Full Text PDFHarnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV.
Drug Deliv Transl Res
January 2025
The Kirby Institute, UNSW Sydney, Sydney, 2052, Australia.
Using the knowledge from decades of research into RNA-based therapies, the COVID-19 pandemic response saw the rapid design, testing and production of the first ever mRNA vaccines approved for human use in the clinic. This breakthrough has been a significant milestone for RNA therapeutics and vaccines, driving an exponential growth of research into the field. The development of novel RNA therapeutics targeting high-threat pathogens, that pose a substantial risk to global health, could transform the future of health delivery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!